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Abstract: Radiodynamic therapy (RDT) is a recent extension of conventional photodynamic therapy,
in which visible/near infrared light irradiation is replaced by a well-tolerated dose of high-energy
X-rays. This enables greater tissue penetration to allow non-invasive treatment of large, deep-seated
tumors. We report here the design and testing of a drug delivery system for RDT that is intended
to enhance intra- or peri-nuclear localization of the photosensitizer, leading to DNA damage and
resulting clonogenic cell kill. This comprises a photosensitizer (Verteporfin, VP) incorporated into
poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) that are surface-functionalized with a cell-
penetrating HIV trans-activator of transcription (TAT) peptide. In addition to a series of physical
and photophysical characterization studies, cytotoxicity tests in pancreatic (PANC-1) cancer cells
in vitro under 4 Gy X-ray exposure from a clinical 6 MV linear accelerator (LINAC) showed that TAT
targeting of the nanoparticles markedly enhances the effectiveness of RDT treatment, particularly
when assessed by a clonogenic, i.e., DNA damage-mediated, cell kill.
Keywords: reactive oxygen species; ROS; singlet oxygen; nanoparticles; radiation; RDT; radiosensiti-
zation; photosensitizer; PLGA; X-PDT; nuclear targeting; TAT peptide; verteporfin; radiation therapy;
radiodynamic therapy
1. Introduction
Photodynamic therapy (PDT) is an approved modality for several pre-cancerous
lesions and solid tumors [1,2], and has non-oncological applications [3]. It employs a
photosensitizer (PS) activated by visible or near-infrared light, most commonly to generate
a singlet oxygen (1O2), a highly cytotoxic reactive oxygen species (ROS) [4]. However, PDT
has had limited clinical application for treating deep-seated, large or disseminated tumors,
due to the shallow penetration of light in tissue that requires technically challenging
endoscopic or interstitial fibre-optic light delivery. The strong tissue- and wavelength-
dependence of the optical absorption and scattering also make it difficult to achieve
complete tumor ablation [5]. In addition, the hydrophobic nature of many molecular PSs
leads to aggregation in biological media, requiring formulations such as liposomes for
efficient delivery to tumors in vivo in order to achieve the maximum treatment efficacy [6].
Radiodynamic therapy (RDT), sometimes also referred to as X-PDT, is a modification
of conventional PDT in that the external activating light source is replaced by high-energy
X-rays, such as those produced by a linear accelerator (LINAC) used in radiotherapy or
by suitable radioisotopes. This concept was introduced by Chen et al. in 2006 [7] and
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has since been investigated by a number of groups. It has showed a range of efficacies
in vitro or in vivo, as reviewed in [8–10], including the use of nanoparticle formulations of
the photosensitizer [11–15]. We previously reported that the photosensitizer Verteporfin,
which is already used for liposomal formulation in clinical practice, can function as an
RDT agent, which is important for accelerating the eventual clinical translation of this
modality [16–19]. Similar findings for other PSs (e.g., protoporpyrin IX) have been reported
by other groups [20–22]. As we have recently reviewed in detail [23], the mechanisms
of ROS generation in RDT are not fully understood but include direct PS activation by
secondary electrons, the use of scintillation nanocrystals to convert X-ray energy into light,
and PS activation by the Cerenkov light generated by high-energy secondary electrons
produced in tissue by MeV X-rays.
Targeted PS delivery systems using antibodies or peptides have been studied in
PDT [24,25] as well as in RDT to increase uptake and selectivity [8,26]. Of particular
interest here, among different cell-penetrating peptides (CPP), the TAT (transactivator
of transcription) peptide is known to be an efficient targeting moiety for translocating
nanoparticles into the cell nucleus via binding to importin α and β (karyopherin) recep-
tors [27–32]. Nuclear targeting in the context of conventional, light-activated PDT has been
described in the earlier literature [33–36], where markedly increased photocytotoxicity
due to direct DNA damage was reported, with up to a >1000-fold reduction in PS dose to
achieve the same in vitro cell kill as that of a non-targeted PS. This approach had not been
reported in the context of RDT, which is the focus of this paper.
For this purpose, we have developed a polymer nanoparticle-based PS formulation
for delivery to the tumor, with a TAT peptide as a nuclear localizing signal. It is based on
polylactic-co-glycolic acid (PLGA), an FDA-approved elastomeric copolymer specifically
used for drug delivery owing to its biocompatibility and biodegradability. PLGA was used
here to encapsulate Verteporfin (VP) [37], and it is expected that these PLGA nanoparticles
(NPs) will allow the encapsulated drugs to accumulate in the tumor in vivo through the
well-known enhanced permeability and retention (EPR) effect [38,39]. They could also
be conjugated into tumor cell-targeting moieties to increase further their efficacy and
specificity. Here, a series of in solu characterization studies were performed, including
NP sizing and zeta potential and stability in biological media. The cellular uptake and
intracellular localization of the PLGA–VP–TAT nanoparticles were then measured as
well as the resulting 1O2 generation and in vitro RDT responses in human pancreatic
cancer (PANC-1) cells. The RTD cytotoxicity was measured by several assays: lipid
peroxidation, MTS, apoptosis/necrosis and, most importantly, DNA double-strand breaks
and clonogenicity. These initial studies reported here focus on comparing the RDT efficacy
of PLGA–VP–TAT) vs. PLGA–VP.
2. Results
2.1. PLGA–VP and PLGA–VP–TAT Nanoparticle Characterisation
An SEM image of the PLGA–VP NPs is shown in Figure 1a. The nanoparticles were
mostly spherical with an average diameter of 85 ± 12 nm. TAT conjugation changed the
value of the zeta potential from (−8.23 ± 0.05) mV to (+2.3 ± 0.8) mV (Figure 1b), which
was attributable mainly to the positively charged TAT amino acids [40]. VP fluorescence
(425 nm excitation, 690 nm emission) was seen with both PLGA–VP and PLGA–VP–
TAT NPs (Figure 1c) and allowed imaging of the cell uptake and localization [16]. The
presence of the TAT peptide on the surface of the PLGA–VP–TAT NPs was confirmed by
absorption spectroscopy (Figure 1d and Supplementary Figure S1) and FTIR spectroscopy
(Supplementary Figure S2). The peak size of the PLGA–VP–TAT NPs in PBS with and
without 10% FBS showed a slight increase during the first 4 h but then remained constant
for the next few 48 h (Figure 1e), indicating that there was no significant aggregation in
biological media. The % release of VP from the PLGA-VP NPs in PBS suspension at 37 ◦C
was plotted as a function of time (Figure 1f), and showed that, after some initial release in
the first 4 h, >95% of the VP remained trapped within the NPs (Figure 1e), likely due to VP
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being highly hydrophobic with a low affinity for the hydrophilic environment outside the
PLGA matrix [41]. This drug release profile is consistent with our previous findings [17].
Figure 1. Characterization of PLGA–VP–TAT and PGLA–VP nanoparticles in solution (a) SEM image, (b) Zeta potential in
water, (c) florescence spectra of VP (425 nm ex/690 nm em) from the NPs in water, (d) absorbance spectra in water, showing
the VP and TAT peaks, (e) PLGA–VP–TAT NP stability in PBS with and without FBS, as measured by the nanoparticle peak
size, (f) % release of VP from PLGA–VP–TAT NPs in PBS at 37 ◦C.
2.2. Cellular Uptake
The uptake of the PLGA–VP and PLGA–VP–TAT NPs was measured at 4 h incubation,
which was found previously to be optimal (i.e., gave the maximum NP uptake) [17]. As
seen in Figure 2, there was no measurable VP signal present in the control group (cells
only). The signal was ~2-fold higher for PLGA–VP–TAT NPs than for the untargeted
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NPs (p = 0.009) (Supplementary Figure S3) and the magnified single-cell images with TAT
targeting showed some VP signal within the nuclei. The enhanced cellular uptake of
the TAT-targeted NPs is attributed to the stronger adsorption onto the cell membrane
due to electrostatic interaction between the cationic TAT peptide and heparan sulfate
proteoglycans (HSPGs) on the cell surface [42].
Figure 2. Representative confocal images showing the uptake of PLGA–VP and PLGA–VP–TAT nanoparticles in PANC-1
cells after 4 h incubation: blue-Hoechst nuclear stain, red-VP fluorescence. Magnified single-cell images are shown on the
right. Scale bar: 50 µm.
2.3. RDT Singlet Oxygen Generation and In Vitro Cytotoxicity
The in vitro therapeutic efficacy of RDT was assessed. The NP dark toxicity and cell
viability after RDT were measured first using the MTS assay. This showed (Supplementary
Figure S4) that, in the absence of X-ray treatment, the nanoformulation resulted in cell
viability of ~90% for PLGA–VP–TAT NPs and >95% for PLGA–VP NPs and PLGA NPs
without VP. For RDT (at 4 Gy) the cell viability was reduced to 75 ± 8% (p = 0.02) and
62 ± 5% (p = 0.007) with PLGA-VP NPs and PLGA–VP–TAT NPs, respectively. The results
of the live/dead cell viability assay are shown in Figure 3a, where it is evident that most of
the control (untreated) cells were viable, whereas >50% of the cells were dead following
RDT with PLGA–VP–TAT NPs (p = 0.02). Detailed images, including all different control
groups, are provided in the Supplementary Figure S5. The results for the various treatment
and control groups are shown in Figure 3b. In particular, the cell death for RDT treatments
with PLGA–VP–TAT or PLGA-VP NPs were 53 ± 12% and 29 ± 15%, respectively.
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Figure 3. Cell viability and singlet oxygen generation following RDT. (a) representative confocal fluorescence image of
live (green) and dead (red) cells following RDT with PLGA–VP–TAT NP and 4 Gy, compared to no-treatment controls,
(b) corresponding cell viability, (c) representative confocal fluorescence image of SOSG fluorescence (green) and nuclear
staining (blue) following 4 Gy RDT with PLGA–VP–TAT NPs compared to untreated controls, (d) SOSG fluorescence in
treated and control cells, * p < 0.05 and ** p < 0.5. Scale bar: 50 µm.
These results are consistent with the singlet oxygen generation in the cells, as mon-
itored with the fluorescent SOSG probe: Figure 3c,d. Supplementary Figure S6 shows
the confocal images of SOSG fluorescence of the various control groups. Less than 5%
increase in SOSG signal was seen with X-rays only compared to untreated control cells,
and increased by ~105% and ~280% in cells undergoing RDT with PLGA–VP NPs and
PLGA–VP–TAT NPs, respectively.
2.4. DNA and Lipid Membrane Damage
Double-strand breaks (DSBs), the most common lethal lesion in DNA following
ionizing radiation exposure [43], were measured following RDT by detecting the presence
of γ-H2AX, a phosphorylated form of the histone H2A variant that forms rapidly at the sites
of DNA DSBs [44]. The results (Figure 4a,b) indicate minimal DNA damage in untreated
control cells. RDT with PLGA–VP NPs resulted in ~2.5-fold increase in signal compared
with radiation (4 Gy) alone (p = 0.01), while RDT using the PLGA–VP–TAT NPs showed
~6-fold increase (p = 0.006 compared to radiation alone; p = 0.04 compared to RDT with
untargeted NPs).
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Figure 4. RDT effects at the cellular level. (a) representative confocal microscopy images showing DNA double strand
breaks indicated by γ-H2AX staining (red: γ-H2AX, blue: Hoechst nuclear stain), (b) quantification of γ-H2AX fluorescence,
(c) lipid peroxidation in the treatment and control groups. Scale bar: 50 µm.
RDT-induced apoptosis and necrosis are shown in Supplementary Figure S7: cells
treated with nuclear-targeted RDT showed significant higher levels of necrotic cell death
than non-targeted RDT or controls, with necrosis being more pronounced than apoptosis.
This reduction in the cell membrane integrity is supported by the measurement of lipid
peroxidation [45] shown in Figure 3d and discussed more in Supplementary Section S8
(Figure S8). Figure 4b shows ~90% increase in lipid peroxidation for RDT using the TAT-
targeted NPs compared to untreated controls, which was significantly higher (p < 0.05)
than RDT with the untargeted PLGA–VP NPs (~40%) or with radiation alone (~20%).
2.5. Clonogenic Response to RDT
The cell viability assays above do not determine the clinically important long-term
response of cancer cells after treatment [12] since they do not account for altered prolifera-
tive capacity or repair of sublethal damage [46]. The results of the clonogenic assay [47]
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are shown in Figure 5. There was a significant difference in the number of colonies
(colonies > 50 cells) following RDT treatment with PLGA–VP–TAT NPs compared to RDT
with untargeted NPs (p < 0.005), X-rays only (p < 0.001), and no treatment (p < 0.001).
Figure 5. Clonogenic assay. (a) example of stained colonies at 14 d following treatment, (b) survival fraction for RDT in
various treatment groups.
3. Discussion and Conclusions
The PLGA-based VP nanoformulation (PLGA–VP) with spherical nanoparticles
<~100 nm diameter was synthesized by an emulsion–evaporation technique. The various
characterization metrics (absorption, fluorescence, FTIR) showed that the hydrophobic
VP molecules were encapsulated successfully within the nanoparticles. Conjugation
of the TAT peptide on the nanoparticle surface resulted in a stable PLGA–VP–TAT NP
formulation as confirmed by the Zeta potential and absorption measurements over
time. The uptake of the nanoparticles in human PANC-1 pancreatic cancer cells was
significantly higher with TAT targeting, including within the cell nuclei, compared to the
non-targeted VP nanoformulation and resulted in significantly greater RDT cytotoxicity
as reflected in both higher DNA and cell membrane damage. With targeting, RDT was
markedly more cytotoxic than the same dose of X-rays without nanoparticles, which was
attributed to increased radiation-induced ROS generation, specifically singlet-oxygen
generation from the VP molecules.
Most importantly for potential clinical relevance, the clonogenic assay results showed
that the cells had only about 10% proliferative capacity after a single 4 Gy dose of TAT–NP-
targeted RDT. This is a substantially higher efficacy than the cytotoxicity measured by the
other cell-death assays that depend on damage to extra-nuclear organelles. In interpreting
this result it should be noted that, consistent with the reported size-dependent nuclear
uptake of nanodrugs facilitated by the TAT peptide [48], not all the targeted NPs were
localized in the nucleus or perinuclear region; hence, the current formulation was not
fully optimized for nuclear-targeted RDT. Reducing the nanoparticle size may increase the
cellular and nuclear uptake and enhance the RDT efficacy further, and these investigations
are in progress. On the other hand, it may be desirable to have some degree of non-nuclear
cell-death pathways (in particular, necrosis) to retain the advantage of immune modulation,
as seen in conventional PDT, to contribute to anti-tumor efficacy [49–52].
Int. J. Mol. Sci. 2021, 22, 6425 8 of 15
In comparing these results with other studies of RDT, those using psoralens are of
note [53]. Psoralens are used clinically in PUVA (Psoralen-UVA) phototherapy for a variety
of benign skin conditions. They work by intercalating into DNA so that cell proliferation is
blocked under ultraviolet-A exposure. X-ray activation of a psoralen, mediated through
MeV X-ray-generated Cherenkov light, showed increased cell death in vitro (as measured
by an adenosine triphosphate luminescence assay of around 20% in breast cancer and 9.5%
in melanoma cells) using 50 µM psoralen and a 2 Gy X-ray dose. Interestingly, also seen
was a 4- to 8-fold increase in the surface expression of major histocompatibility complex I
(MHC I), which is related to immune response [53]. In vivo studies using a syngeneic 4T1
breast cancer model showed that a psoralen-based RDT reduced tumor growth [54].
In general, RDT in its various forms with different photosensitizers has shown both
in vitro and in vivo efficacy across in a range of tumor types [16–18,20–22,55–58]. Never-
theless, it is not clear that the efficacy is enough to translate into a stand-alone treatment
using a well-tolerated (e.g., <10 Gy) dose of high-energy (MeV) X-rays combined with
systemic administration of an approved clinical photosensitizer. There is, however, still
the option to use phototherapeutic agents as a novel form of radiation sensitizer for use in
conventional fractionated radiation therapy depending on how often the photosensitizer
needs to be administered. The findings from our initial study here suggest that active
targeting of nanoparticles incorporating the photosensitizer could be an effective option to
enhance the efficacy of RDT, especially to destroy the proliferative capacity of tumor cells.
We recognize that the above results, while encouraging, do not represent definite
proof of nuclear-targeted RDT, since there are several potentially confounding effects that
need to be considered. Thus, while the fluorescence microscopy of the VP distribution
suggests a higher nuclear localization with the TAT-conjugated NPs, true quantification
in this approach is challenging [59]. Cellular disaggregation followed by quantitative
fluorimetry of the organelle fractions [60] would be a more robust assay. In addition, the
fact that the DNA double-strand breaks increased compared to the sole X-ray control, even
without the TAT, suggests that other effects may be occurring. For example, X-irradiation
is known to increase cellular and nuclear membrane permeability [61,62] such that it could
allow a degree of nuclear internalization even without the TAT. The greater DNA damage
with the TAT NPS may then reflect simply a greater total-cell uptake rather than a specific
nuclear localization. One way to control this would be to measure accurately the total cell
uptake of the NPs and then adjust the relative concentration of the targeted and untargeted
NPs to give the same total uptake at the time of X-irradiation. Again, such experiments
are planned.
The next steps also include further optimization of the nanoformulation and evaluation
of RDT efficacy in vivo and to other tumor types. If successful, a nuclear-targeted RDT
has potential as a novel treatment option, either as a stand-alone or to enhance the efficacy
of fractionated radiotherapy, including in the treatment of deep-seated tumors such as in
the pancreas.
Finally, as with most anti-cancer therapies, the tumor selectivity of nuclear-targeted
radiodynamic therapy will be an important issue for clinical translation. Even with accurate
spatial localization of current radiation therapy delivery, if there is significant nanoparticle
accumulation in normal organs, there will be activation and potential cytotoxicity in normal
tissue lying along the radiation beam paths in addition to that caused by the radiation, itself.
Hence, it is likely that tumor-cell targeting, in addition to nuclear localization by the TAT or
other nuclear-localizing strategies, will be required to achieve differential uptake beyond
that caused by the EPR effect. There is also the risk of enhanced skin phototoxicity due to
nuclear uptake that must be addressed. Direct intratumoral administration of nanoparticles
or intra-arterial delivery may be options to mitigate these off-target toxicities. The dark (no
light, no X-rays) toxicity should, on the other hand, be minimal, given the excellent safety
profile of the components in the formulation
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4. Materials and Methods
4.1. Materials
Resomer® RG 504 H; Poly(D,L-lactide-co-glycolide) (PLGA; #719900), poly(vinyl al-
cohol) (PVA; #363138), dichloromethane (DCM; #650463), Verteporfin (VP; #SML0534),
dimethyl sulfoxide (DMSO; #D2650), 1-[3-(Dimethylamino)propyl]-3-ethylcarbodiimide
methiodide (EDC; #165344), N-Hydroxysuccinimide (NHS; #130672), human pancreatic
ductal adenocarcinoma cell line (PANC-1), Dulbecco’s Modified Eagle’s Medium—high
glucose without L-Glutamine (#D5671) and Gentian violet (#G2039) were purchased from
Sigma-Aldrich (St. Louis, MI, USA). Singlet oxygen sensor green probe (SOSG; #S-36002),
NucBlue™ Live ReadyProbes™ Reagent (#R37605), LIVE/DEAD™ Viability/Cytotoxicity
Kit for mammalian cells (#L3224), HCS DNA Damage Kit (H10292), Image-iT™ Lipid Perox-
idation Kit for live cell analysis (C10445), DPBS with calcium and magnesium (#14040182),
DPBS with no calcium or magnesium (#14190250), TrypLE™ Express Enzyme (1X) with
no phenol red (#12604021), L-Glutamine, 200 mM (#25030081) and Fetal Bovine Serum
(FBS) qualified US origin (#26140079) were purchased from Life Technologies (Carlsbad,
CA, USA). Apoptosis/Necrosis Assay Kits (blue, red, green) (ab176750) and CellTiter 96®
AQueous One Solution Assay were purchased from Abcam (Cambridge, UK) and Promega
(Madison, WI, USA) respectively. Except as otherwise noted, all commercial assays were
performed according to the manufacturers’ instructions.
4.2. Methods
4.2.1. Nano Formulation and Conjugation
We prepared PLGA, PLGA-VP and PLGA–VP–TAT nanoparticles using a published
solvent-evaporation single-emulsion method with slight modifications [17]. Briefly, a
3 mM stock solution of VP (2.2 mg/1 mL) in DMSO and 5% PVA (5 g/100 mL) solution in
water were prepared. Later, 30 mg of PLGA was dissolved in 3 mL of DCM and 200 µL
of VP stock was added dropwise while vortexing. This mixture was added dropwise to
12.5 mL of 5% PVA and vortexed thoroughly before sonication for 1.5 min (3 × 30 s) at an
output power of 200 W using a microtip-probe sonicator (Branson Digital Sonifier, S-250D;
Emerson Industrial Automation, CT, USA). The resulting solution was placed overnight in
a shaker (300 rpm) to evaporate the DCM, after which it was centrifuged at 12,500 rpm for
20 min and redispersed in water. This washing procedure was repeated twice and finally
the NPs were redispersed in 12 mL water to form the PLGA–VP NPs and stored in the dark
at 4 ◦C. A PLGA NP stock solution was also prepared using the same procedures except
for the addition of VP and served as a control.
The PLGA–VP–TAT nanoparticles were prepared by conjugating the TAT peptide to
the nanoparticle surface through an EDC–NHS reaction. EDC couples NHS to a carboxylic
group in the PLGA, forming a highly stable NHS ester, and this allows efficient conjugation
to primary amines in the TAT peptide. The conjugation procedure was as follows: 2 mL
of PLGA–VP stock was centrifuged, the supernatant was removed, and 1.2 mL PBS was
added. Then, 30 mg of NHS and 60 mg of EDC were added before incubation for 2 h in
an orbital shaker (200 rpm). A 100 µM TAT stock was first prepared, then 60 µL of TAT
stock in 200 µL of PBS was added. This mixture was kept overnight in a shaker (150 rpm),
washed, centrifuged at 12,500 rpm for 10 min, redispersed in 2 mL of DI water and stored
in the dark at 4 ◦C. The main formulation steps are illustrated in Figure 6.
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Figure 6. Schematic illustration of PLGA–VP–TAT nanoparticle formulation.
4.2.2. Characterization
The size and zeta potential of the NPs were measured using dynamic light scattering
(DLS) (Zetasizer Nanoseries; Malvern Panalytical Ltd, Malvern, Worcestershire, UK). All
measurements were performed in triplicate at 25 ◦C. The fluorescence emission spectrum of
VP (425 nm excitation) in various nanoformulations was measured in a spectrofluorometer
(Cary Eclipse Spectrophotometer; Varian, Inc., Palo Alto, CA, USA) in a quartz cuvette at
room temperature. The absorption spectra of different NPs were measured in a double-
beam spectrophotometer (Cary UV–VIS–NIR; Agilent, Santa Clara, CA, USA) using 1 cm
pathlength quartz cuvettes. The conjugation of TAT to the surface of the NPs was confirmed
using both absorption and Fourier Transform InfraRed (FTIR) spectroscopy.
4.2.3. In vitro VP Release from PLGA NPs
To begin, 500 µL of PLGA–VP–TAT NPs was centrifuged and redispersed in PBS, with
and without 10% FBS, to mimic physiological conditions. The solution was placed in a
Lyzer tube (Midi Pur-A-Lyzer 6000 Dialysis Kit) that was placed in a 50 mL tube with
15 mL of PBS and incubated at 37 ◦C for different times (1, 2, 3, 4, 5, 24 and 30 h). An
aliquot of PBS was taken for fluorescence measurement of the released VP at each time
point. The percentage of VP release was calculated as
% VP release =
100 (VPF)
(VPc)
where VPF and VPc represent, respectively, the peak fluorescence emission intensities of
VP in PBS and in a control sample that was prepared by dispersing PLGA–VP NPs in
15 mL PBS and 200 µL DMSO.
4.2.4. Nanoparticle Stability
The stability of the PLGA–VP–TAT NPs in PBS, with and without 10% FBS, was
measured as follows. 1 mL PLGA–VP–TAT in water was centrifuged and then dispersed
in the media and then kept in a water bath at 37 ◦C, with the size was checked at regular
intervals up to 48 h to test for aggregation.
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4.2.5. X-Irradiation
All irradiations were performed using a clinical 6 MV LINAC at the Genesis Cancer
Care, Macquarie Hospital, Sydney, Australia at 4 Gy, representing a well-tolerated low
dose compared to a typical clinical dose of 50–70 Gy in 2 Gy fractions over several weeks.
4.2.6. Cell Culture
Human pancreatic cancer cells, PANC-1 were grown at 37 ◦C with 5% CO2 in media
comprising DMEM (without L-glutathione) mixed with 10% FBS, 1% antibiotic–antimycotic
and 1% L-glutathione. At 80% confluence, the cells were transferred either to 35 mm petri
dishes or 96-well plates, depending on the experiment. A 4 µM concentration of VP
was used for all in vitro studies and all experiments were performed under minimum
lighting conditions to minimize photobleaching and direct PDT effects. Laser-scanning
confocal fluorescence microscopy (FV3000; Olympus, Tokyo, Japan) was used in various
stages of the PS uptake and in vitro RDT-response assays, with appropriate excitation
and detection wavelengths, for which the microscope settings (laser power, photodetector
gain, integration time) were fixed for each assay. Image J software was used for analysis
and quantification.
4.2.7. Singlet Oxygen Measurements
The singlet oxygen sensor green probe (SOSG) was used to detect 1O2 generation in
solu and in vitro, measuring its fluorescence emission at 525 nm under 488 nm excitation.
For this, a stock solution of SOSG (500 µM) was made by adding 660 µL methanol into an
SOSG vial and diluting it to 8 µM that was found previously to be optimal both in solu and
in vitro [15]. Controls included NPs only, X-rays only and cells only.
4.2.8. Nanoparticle Cellular Uptake and Localization
Cells were seeded into 35 mm2 petri dishes and grown to 60% confluence. The growth
medium was replaced with a fresh medium containing the NPs and the cells were incubated
for 4 h. The control cells were kept in a fresh culture medium without NPs. Cells were
then washed 3 times. Fresh medium was added, and the cells were incubated overnight.
NucBlue™ Live ReadyProbes™ Reagent was added to stain the cell nuclei and the cells
were imaged with 405 nm excitation, measuring the fluorescence (430–480 nm) in the
nuclear region as well as the VP fluorescence (650–700 nm).
4.2.9. Viability MTS Assay
Cells were seeded in 96-well plates at 10,000 cells/well and incubated for 4 h with or
without NPs. The treatment (with PLGA–VP–TAT NPs) and controls (cells only, cells with
PLGA NPs, cells with PLGA–VP NPs) were X-irradiated. The cell viability was measured
immediately using the MTS assay (CellTiter 96® AQueous One Solution), reading the
absorbance at 490 nm on a plate reader. Cell viability was calculated relative to non-
treatment controls.
4.2.10. Live/Dead Assay
A LIVE/DEAD™ Viability/Cytotoxicity Kit was used to assess the RDT cytotoxicity.
Cells were seeded at 1 × 105 cells/mL in a 35 mm petri dish and grown to 60% confluence.
After NP incubation for 4 h followed by X-irradiation, the assay was run (following the
manufacturer’s protocol), and the cells were imaged (488 nm excitation and 520 and
625 nm emission).
4.2.11. Apoptosis/Necrotic Assay
Using the same cell preparation and treatments as for the live/dead assay, the apopto-
sis/necrotic assay (ab176750) was performed immediately after X-irradiation. The cells
were imaged and live (405 nm excitation/450 nm emission), apoptotic (490 nm/525 nm)
and necrotic (630 nm/690 nm) cells were counted.
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4.2.12. DNA Damage Assay
Double-strand DNA breaks were assayed using the HCS DNA damage kit (H10292)
immediately following RDT treatment, by immunostaining (according to the manufac-
turer’s protocol) for phosphorylated γH2AX and imaging the cell fluorescence (555 nm
excitation, 565 nm emission).
4.2.13. Lipid Peroxidation Assay
The Image-iT™ Lipid Peroxidation Kit for live cell analysis was used to assess the
peroxidation of lipid membranes. In this assay, the fluorescence from live cells shifted from
red (590 nm) to green (510 nm) under excitation at 580 and 488 nm, respectively. The cells
were prepared as for the live/dead cell assay, and the red/green, i.e., reduced/oxidized,
ratiometric image yielded the percent lipid peroxidation relative to untreated controls.
4.2.14. Long-Term Proliferation
Clonogenicity was used to assess the long-term proliferative capacity of the cells.
Following RDT treatment with a starting density of 500 cells/dish, cells were incubated
for 2 weeks, with the medium changed every other day. After day 14, the cells were fixed
with 4% formaldehyde at room temperature for 15 min, followed by washing with PBS
(+Ca and +Mg). Colonies were then stained with Gentian violet (5 drops per dish) for
30 min, washed to remove excess stain and dried at room temperature for 1 h. Colonies
with >50 cells were then counted manually and the survival fraction was calculated as [63]
Survival fraction =
Number of colonies formed after treatment
No of cells seeded × Plating efficiency
where the plating efficiency is the percentage of seeded cells that survived to form colonies
under no-treatment conditions.
4.2.15. Statistical Analysis
All measurements were repeated at least in triplicate, and results were presented as
a mean ± 1 standard deviation. Two sample t-tests were applied, with p < 0.05 being
considered statistically significant.
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